Rheumatology Resources and Support

J&J withMe in your country

The Immune System and Immune-mediated inflammatory diseases

The immune system is your body’s defence against disease and pathogens. In immune-mediated inflammatory diseases, the immune system wrongly attacks its own tissues and causes inflammation, pain, and can result in loss of function.
Nearly 1 in 10 people in Europe are living with an immune-mediated inflammatory disease.
Living with an immune-mediated inflammatory disease has a similar impact on psychological and physical functioning to cancer, heart disease and hypertension.

Johnson & Johnson and Rheumatological Diseases

Johnson & Johnson’s worldwide leadership in immunology has been established from a 30-year heritage of innovation and scientific breakthroughs. For over three decades, we have been a world leader in the development of biologic treatments that have modified the imbalance in patients’ immune systems and have transformed their lives.

We foster active collaborations with academia, emerging companies, patients, and patient groups to accelerate innovation and achieve our shared goals in tackling immune-mediated disease.

Explore our Disease Areas

A man and a woman doing yoga with eyes closed

Rheumatoid Arthritis

a woman with ear plugs in and clicking on her a watch

Axial Spondyloarthritis

Psoriatic Arthritis

References

[1]

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.

[2]

Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.

[3]

Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.

[4]

Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.

[5]

DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.

[6]

Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.

[7]

Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.

[8]

NHS Inform. Diarrhoea. Available at: https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/diarrhoea/. Last accessed: November 2024.

[9]

Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.

[10]

Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.

[11]

Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.

[12]

Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.

Get In Touch